FC binding fragments comprising a PD-L1 antigen-binding site
US11548948B2 · kind B2 · utility
8Cited by
13References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 19, 2018 |
| Grant date | Jan 10, 2023 |
| Priority date | — |
| Expiry date | Mar 9, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2318/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.